Aetna Fertility Billing: Coverage Rules and Authorization Tips

Aetna insures a significant share of U.S. fertility patients through its commercial, exchange, and Medicare Advantage products. Getting Aetna fertility billing right requires understanding three variables that interact with every claim: the Clinical Policy Bulletin (CPB) that defines medical necessity for the member's specific plan type, the prior authorization requirements that apply to ART procedures, and whether the member's group health plan is fully insured — governed by Aetna's CPB and applicable state mandates — or self-funded, where the employer's plan document controls coverage and may diverge substantially from Aetna's standard policy. Missing any one of these variables is the leading cause of Aetna fertility claim denials at both the authorization and adjudication stages.

Aetna Clinical Policy Bulletins for Fertility Services

Aetna publishes Clinical Policy Bulletins (CPBs) that define covered fertility services, medical necessity criteria, and documentation requirements for fully insured plans. Billing staff and authorization coordinators should know the relevant CPBs by number because Aetna reviewers cite them in every adverse determination letter. CPBs are updated quarterly; always download the current version from Aetna's provider portal before submitting an authorization — the policy version in effect on the date of service controls coverage, not the version your team printed out six months ago.

• CPB 0327 – Infertility: Aetna's primary fertility policy for fully insured plans. Defines the diagnostic criteria for infertility, step-therapy requirements (IUI cycles before IVF), bypass diagnoses, and covered ART service categories. This is the document your authorization staff must know before submitting any IVF or IUI auth.
• CPB 0086 – Genetic Testing: Governs PGT-A (CPT 81479), PGT-M, and PGT-SR authorization criteria. Medical necessity requirements for PGT are separate from and in addition to the IVF authorization requirements under CPB 0327. Do not assume a PGT-A request will be approved simply because IVF is authorized.
• CPB 0352 – Gamete and Zygote Intrafallopian Transfer: Covers GIFT and ZIFT procedures where relevant. Most modern fertility practices do not perform these procedures, but the CPB may be cited in adverse determination letters for combination transfer cases or historical service disputes.
• CPB 0370 – ART Medications: Governs fertility drug reimbursement under the medical benefit, including J-codes for injectable gonadotropins. Practices billing Gonal-F, Menopur, or Follistim as medical benefit claims should verify current CPB 0370 criteria before each authorization cycle, as covered medications and billing pathways have shifted between versions.

Prior Authorization Requirements by Service Type

Aetna requires prior authorization for most ART procedures on fully insured commercial plans. The table below reflects Aetna's standard authorization requirements under CPB 0327; always verify against the member's specific plan, as self-funded employer groups may impose different or additional authorization requirements not reflected in the standard policy.

Step Therapy: IUI Cycles Required Before Aetna Will Authorize IVF

For fully insured Aetna plans without a state fertility mandate override, CPB 0327 requires documentation of failed conservative treatment before IVF authorization will be issued. The documentation Aetna requires for each IUI cycle is specific: stimulation protocol used, peak estradiol or dominant follicle count, insemination parameters including total motile sperm count at the time of insemination, and confirmation of a failed cycle outcome. A summary letter from a referring OB/GYN stating the patient "completed 3 IUI cycles" does not satisfy this requirement — the actual treatment records must be submitted. If the IUI cycles were performed at a different practice, obtain the complete records before submitting the IVF authorization.

• Timed intercourse: 12 months documented for patients under 35; 6 months for patients ages 35–39; requirement may be waived for patients 40 and older under many Aetna plan designs.
• IUI cycles: Minimum 3 cycles with stimulation in couples where male factor and tubal anatomy do not preclude IUI success. Each cycle must be individually documented with stimulation protocol, peak response, insemination parameters, and failed cycle confirmation.
• Bilateral tubal occlusion (ICD-10 N97.1): Bypasses IUI step-therapy entirely. Documentation must include HSG or diagnostic laparoscopy results confirming bilateral occlusion.
• Severe male factor (ICD-10 N46.01, N46.11): Total motile sperm count below 1 million on two semen analyses, or severe morphology defects meeting Aetna's CPB threshold, bypasses the IUI requirement. Attach both semen analysis reports with the authorization submission.
• Diminished ovarian reserve (ICD-10 E28.39): AMH below 1.0 ng/mL or antral follicle count below 7 on a cycle day 2–3 ultrasound. Attach the actual lab report with numeric AMH value and the ultrasound report with specific follicle count — narrative descriptions stating "AMH is low" are not accepted by Aetna reviewers.
• Premature ovarian insufficiency (ICD-10 E28.31x): Bypasses step-therapy. Requires documentation of FSH elevation and clinical findings consistent with POI.
• Prior failed surgical correction of tubal disease, or prior ectopic pregnancy: Attach operative reports, pathology reports, and radiology findings as applicable.
• Known BRCA1/BRCA2 mutation carrier with documented intent to perform PGT-M: Aetna may approve IVF without IUI step-therapy when the primary indication is preimplantation genetic testing for a high-penetrance hereditary cancer syndrome.

ICD-10 Code Selection for Aetna Fertility Claims

ICD-10 code selection is not a clerical function in Aetna fertility billing — it directly determines whether step-therapy applies, which bypass diagnoses qualify the patient for direct IVF authorization, and how the authorization routes internally (nurse reviewer versus medical director). The REI physician must confirm the primary diagnosis code before every authorization submission, not just the clinical description. A code mismatch between what the physician documented and what the billing team submitted is both a compliance risk and a denial risk.

Fully Insured vs. Self-Funded Plans: Why Plan Type Changes Everything

Aetna administers both fully insured plans — where Aetna bears the insurance risk and CPB 0327 controls coverage — and self-funded employer plans — where the employer bears the financial risk and Aetna administers claims as a third-party administrator. Self-funded plans are governed by the federal ERISA statute, not by state insurance law, which means state fertility mandates do not apply to them regardless of where the employer or the employee is located. A member with an Aetna insurance card whose employer has a self-funded plan may have zero fertility coverage even if they live in a state with an unlimited IVF mandate — because the mandate only applies to Aetna's fully insured products, not to the employer's self-funded plan document.

Identifying plan type before submitting an authorization is not optional — it determines whether CPB 0327 applies to the member at all. Self-funded plan documents are not publicly available; the practice must request the fertility benefit section of the Summary Plan Description (SPD) from the member's HR department, or call Aetna provider services and ask specifically whether the group number is a fully insured or ASO (Administrative Services Only) arrangement. The member's insurance card may carry an ASO or Administrative Services notation. Submitting a complete IVF authorization package for a self-funded plan member whose employer has excluded fertility coverage results in a denial that no amount of clinical documentation will overturn — because the denial is based on the plan document exclusion, not on a clinical determination, and the plan document controls under ERISA.

Common Aetna Fertility Denial Reasons and Prevention Strategies

• No prior authorization obtained: Aetna denies claims for CPT 58970, 58974, 58976, and 89250 when no authorization was obtained in advance. These denials cannot typically be retro-authorized — the claim is written off. Build a trigger in your practice management system that blocks any ART procedure charge entry without a matching authorization number.
• Authorization obtained but CPT codes do not match the claim: The auth letter covers CPT 58970 and 58974 but the claim includes 89250 (embryology) and 89281 (ICSI), which were not listed on the authorization request. Pull the auth letter and compare it against every planned CPT code before the retrieval date — not after the claim is denied.
• Step-therapy documentation is incomplete: IUI cycle records submitted without stimulation protocol, peak follicle response, insemination parameters, or cycle outcome documentation. Obtain complete records from the treating practice before submission — summaries and attestation letters do not satisfy Aetna's documentation standard.
• Wrong ICD-10 code activates step-therapy: N97.9 submitted when N97.1 (tubal factor) or E28.39 (DOR) would have bypassed the IUI requirement. Confirm the specific ICD-10 code — not just the clinical description — with the REI physician before every authorization.
• Authorization expired before date of service: Aetna IVF authorizations are typically valid for 90 days from the issue date. If the cycle is delayed, the authorization must be extended before the date of service. Build a 30-day-out expiration alert for all open Aetna IVF authorizations in your scheduling or authorization tracking system.
• FET assumed to be covered under original IVF authorization: The practice assumes the frozen embryo transfer is covered under the retrieval authorization from a prior cycle. FET cycles at Aetna require a separate authorization — obtain it at the start of the monitoring cycle, not at transfer.
• Self-funded plan excludes fertility coverage: No clinical documentation, appeal, or peer-to-peer review will overturn a plan document exclusion under ERISA. Identify this before the consultation, not after the claim is denied and the service has already been rendered.
• Lab component denied as unauthorized: 89250 (IVF culture and fertilization) requires authorization. Practices that list only 58970 and 58974 on the authorization request and then bill 89250 separately on the laboratory claim are submitting an unauthorized service — it will be denied and the appeal window is limited.

Authorization Submission Protocol for Aetna IVF and FET Cycles

A standardized Aetna authorization submission protocol reduces denial rates more reliably than any other single intervention in Aetna fertility billing. The following steps reflect current best practices for Aetna fully insured commercial plans; adapt as needed for specific employer group plan designs identified during benefit verification.

• Submit the IVF authorization package at least 14 business days before the anticipated retrieval date. Aetna's standard turnaround for fertility authorizations is 10–14 business days; expedited review is not a substitute for timely submission and may not apply to fertility services under most commercial plan designs.
• List all anticipated CPT codes on the authorization request simultaneously: 58970 (oocyte retrieval), 89250 (fertilization and culture), 89258 (cryopreservation if applicable), 58974 (fresh embryo transfer if planned), 89280 or 89281 (ICSI if applicable). Do not submit retrieval codes first and add embryology codes in a second request — the second submission often generates a separate authorization number, creating a code mismatch at claim adjudication.
• Submit FET authorization as a completely separate request at the start of each frozen transfer monitoring cycle. Include CPT 58976 (cryo-thaw embryo transfer) and 89352 (thawing of cryopreserved embryo) on the FET authorization. Do not submit the FET auth at the same time as the retrieval auth months in advance — Aetna's 90-day validity window may expire before the FET cycle occurs.
• Attach clinical documentation proactively with every submission: the physician's criterion-specific letter of medical necessity, complete IUI cycle records for each required cycle, AMH lab report with numeric value and collection date if DOR is the bypass diagnosis, antral follicle count from a cycle day 2–3 ultrasound report, and the patient's IVF treatment plan. Incomplete submissions are the leading cause of Aetna authorization delays.
• Follow up on every submitted authorization within 5 business days. Do not assume silence means the auth is pending review — Aetna may close incomplete submissions without notifying the practice. Assign a team member to check the status of every pending auth at the 5-business-day mark using Aetna's NaviMedic provider portal.
• Obtain and retain the written authorization letter — not just the verbal authorization number. Verify that the letter explicitly lists the approved CPT codes, the approved ICD-10 codes, the authorized service date range, and the authorizing facility or provider. A verbal auth number without a written confirmation provides limited protection at adjudication if code or date discrepancies arise.

Aetna Fertility Benefit Verification Checklist

Complete this checklist at the initial consultation for every new Aetna patient, and reverify at the start of each treatment cycle. Benefit information changes at plan renewal, which is typically January 1 for most employer groups but may occur on a different anniversary date — a benefit that was accurate in January may be materially different if the employer renewed mid-year or switched products.

• Plan type: fully insured or self-funded (ASO)? If self-funded, request the SPD fertility benefit section from the employer before scheduling any treatment — do not proceed on the assumption that Aetna's standard CPB applies.
• State mandate applicability: Is the member enrolled in a fully insured plan in a state with a fertility insurance mandate? Confirm that coverage for this group reflects the current mandate requirements, including cycle limits, diagnostic criteria, and covered services.
• IVF benefit design: Is IVF covered? How many lifetime cycles? Is there a per-cycle or lifetime dollar maximum? Does the plan count a cancelled cycle as a used benefit cycle?
• FET benefit: Are frozen embryo transfers covered under the same benefit allocation as IVF retrievals, or are they counted separately? Some Aetna plans count each FET as an independent cycle against the lifetime maximum.
• Step-therapy requirement: Does the plan require IUI cycles before IVF? How many? Which bypass diagnoses are recognized under this specific plan?
• Network status: Is the fertility practice in-network for this specific Aetna product? Is the embryology laboratory in-network and on a separate contract? Some Aetna products require the lab to be credentialed at the same network tier as the clinical practice.
• Pharmacy vs. medical benefit for injectable medications: Are gonadotropins covered under the medical benefit (J-codes billed by the practice) or under the pharmacy benefit (patient uses a specialty pharmacy)? This varies widely across Aetna products and employer group designs.
• Deductible and out-of-pocket status: What is the current year-to-date deductible accumulation? What is the out-of-pocket maximum and current accumulation? What is the patient's coinsurance responsibility for ART services after the deductible is met?
• Coordination of benefits: Is Aetna primary or secondary? Does a secondary payer exist? If COB applies, verify the order of benefits and the secondary payer's fertility benefit before submitting any claims.

What Aetna Gets Right — and Where Practices Lose Revenue

Aetna's fertility policies are more transparent than many commercial payers — the CPBs are publicly accessible, the step-therapy criteria are documented in writing, and the bypass diagnoses are explicitly listed. Practices that invest in reading the current CPB 0327 before each authorization cycle, building payer-specific authorization checklists that mirror Aetna's CPT code requirements, and training staff to identify plan type before any authorization submission will see Aetna first-pass approval rates consistently above 85 percent. Practices that treat Aetna like a generic commercial payer — submitting generic auth requests, using N97.9 for every patient, and assuming one authorization covers all service codes — will lose revenue to preventable denials on every cycle. The documentation Aetna requires is demanding but consistent. Meeting it front-end is far less costly than recovering revenue on the back end.